# Use of an Ultra-rapid BRCA1/2 Status Screening Test in Diagnostic and Theranostic Indication: Performance and Interest for Patients and Practitioners

> **NCT06111417** · — · RECRUITING · sponsor: **Centre Georges Francois Leclerc** · enrollment: 150 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **OTHER:** Questionnaires
- **OTHER:** Communication of the results of the BRCA1/2 ultra rapid test

## Key facts

- **NCT ID:** NCT06111417
- **Lead sponsor:** Centre Georges Francois Leclerc
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-12
- **Primary completion:** 2026-09-12
- **Final completion:** 2026-09-12
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06111417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06111417, "Use of an Ultra-rapid BRCA1/2 Status Screening Test in Diagnostic and Theranostic Indication: Performance and Interest for Patients and Practitioners". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06111417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*